Hisun drops license option after ThermoDox HCC failure but door still ajar
This article was originally published in Clinica
Executive Summary
Following the missed primary endpoint in Celsion's Phase III HEAT trial with its ThermoDox technology in hepatocellular carcinoma (HCC), the US firm's Chinese partner Hisun Pharmaceutical has decided to not to pursue an option deal for the licensing of the product.